Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U5A small nuclear 1 (RNU5A-1) encodes the U5A variant of small nuclear RNA (snRNA), a non-coding, uridine-rich RNA essential for the function of the major spliceosome in eukaryotic cells[1][4][7]. U5 snRNA forms part of the U4/U5/U6 tri-snRNP complex, which mediates the removal of introns from pre-messenger RNA through the splicing reaction[1][7]. The U5 snRNA specifically plays a critical role in aligning exons by binding to both the 5' and 3' splice sites, ensuring precise ligation during catalysis[5]. Variants in RNU5A-1 have been associated with neurodevelopmental disorders, as pathogenic de novo mutations are observed in patients with clinical features consistent with splicing defects, making it a strong candidate gene but not an established therapeutic target[5]. U5 snRNA, like other snRNAs, functions as part of small nuclear ribonucleoproteins (snRNPs) and does not code for proteins nor act as a receptor, enzyme, or classical drug target[1][4]. There are currently no drugs that directly target RNU5A-1, and no known biomarkers or safety concerns linked to direct manipulation of this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U5A small nuclear 1 (RNU5A-1).